Medical/Pharmaceuticals
Frost & Sullivan grants the Global Targeted Molecular Fluorescent Tracer R&D Leadership Award to Nanjing Nuoyuan Medical Devices Co., Ltd.
SHANGHAI, Sept. 9, 2024 /PRNewswire/ -- Frost & Sullivan is pleased to announce that the 18th Growth Innovation Leadership (GIL) Summit and the 3rd New Investment Event (NIE 2024), was held inShanghai from August 27 to 30, 2024, co-hosted by LeadLeo. Based on research and analysis of the global ...
2024-09-09 20:06
1834
Frost & Sullivan grants the Global Biologics CDMO Technology Leadership Award to BiBo Pharma
SHANGHAI, Sept. 9, 2024 /PRNewswire/ -- Frost & Sullivan is pleased to announce that the 18th Growth Innovation Leadership (GIL) Summit and the 3rd New Investment Event (NIE 2024), was held inShanghai from August 27 to 30, 2024, co-hosted by LeadLeo. Based on research and analysis of the global ...
2024-09-09 19:51
2104
Sirsram Medical announces NMPA approval for DAXXIFY®
Marking the introduction of the world's first and only peptide-powered botulinum toxin product to Mainland China HONG KONG, Sept. 9, 2024 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical aesthetic solutions announced today that the National M...
2024-09-09 19:46
3025
Intelligent Technology Empowers the Future of Rehabilitation: Siyi Intelligence (Syrebo) Shines at WRRC 2024
i-CREATe & WRRC 2024 SHANGHAI, Sept. 9, 2024 /PRNewswire/ -- Siyi Intelligence (Syrebo) played a prominent role at the International Convention on Rehabilitation Engineering and Assistive Technology (i-CREATe 2024) & the World Rehabilitation Robot Convention 2024 (WRRC 2024), held inShanghai fro...
2024-09-09 17:41
2476
MGI Launches New Nanopore Sequencing Products with Advanced CycloneSEQ Technology
SHENZHEN, China, Sept. 9, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced the global rights to commercialize and distribute the new sequencing products CycloneSEQ-WT02* and CycloneS...
2024-09-09 16:24
2043
A. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe
Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians with a urine test to detect and monitor recurrence of bladder cancer and upper tract urothelial carci...
2024-09-09 15:00
1617
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
TAIPEI, Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment tothe United States of its new ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension, 0.05% (APP13007), manufactured by Bora P...
2024-09-09 15:00
2204
Australia Urged to Lead Global Effort Against Childhood Dementia
CANBERRA, Australia, Sept. 9 2024 /PRNewswire/ -- A groundbreaking new report, "State of Childhood Dementia inAustralia 2024," released today at Australia's Parliament House inCanberra by the Childhood Dementia Initiative, has revealed the devastating impact of childhood dementia on Australian fa...
2024-09-09 15:00
1715
Three Study Results Abstracts From Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) At 2024 ESMO Released Today
CHENGDU, China, Sept. 9, 2024 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2024 will be held inBarcelona, Spain from September 13 to 17, 2024. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd（"Kelun-Biotech", 6990.HK）will present the following results of its anti-TROP...
2024-09-09 14:27
2184
Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress
* The study involved end-stage oncology patients with no other suitable treatment options. * In this Phase Ib study, Pidnarulex (CX-5461) demonstrated acceptable clinical tolerability and showed preliminary signs of efficacy, even in patients who had previously failed treatment with PARP inhi...
2024-09-09 10:33
2504
Antennova to Present Latest Data of ATN-037 in a Mini Oral Presentation at ESMO Congress 2024
BOSTON, Sept. 8, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced thatit will present the latest data of CD73 small molecule inhibitor ATN-037 in a Mini Oral presentation at the 2024 European Society of Medical Oncology Congress (ESMO Congress 2...
2024-09-09 08:30
1727
ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
ROCKVILLE, Md. and SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced that it will present the latest c...
2024-09-09 08:25
3174
Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024
HONG KONG, Sept. 8, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combination with chemotherapy, for the perioperative treatment of ...
2024-09-09 02:17
2146
Bc Babycare Marks a Stellar Debut at Germany's Kind+Jugend 2024
COLOGNE, Germany, Sept. 6, 2024 /PRNewswire/ -- Bc Babycare, a leader in innovative products for mothers and babies, made a remarkable debut at Kind+Jugend 2024, the premier international trade fair for baby and toddler outfitting, which opened inCologne, Germany, on September 3. The brand capti...
2024-09-06 23:22
2909
Vieworks Unveils Digital Pathology Scanner LUCEON at ECP 2024
ANYANG-SI, South Korea, Sept. 6, 2024 /PRNewswire/ -- Vieworks, a leading name in bioimaging solutions, is to set a new standard in the digital pathology field with the launch of its high-speed slide scanner LUCEON 510. Vieworks will be making its debut as a digital pathology solution provider at...
2024-09-06 22:00
6661
Sciwind Biosciences Announces Oral Presentations at the European Association for the Study of Diabetes 60th Annual Meeting (EASD 2024)
HANGZHOU, China and SAN FRANCISCO, Sept. 6, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present positive results from a ...
2024-09-06 10:10
3094
Akeso to Present Data from 13 Clinical Studies at ESMO 2024, Featuring its Internally Developed Cadonilimab, Ivonescimab, Ligufalimab, and other I/O Antibodies
HONG KONG, Sept. 5, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) will showcase promising results from 13 clinical studies on its internally developed PD-1/CTLA-4 bispecific antibody cadonilimab, PD-1/VEGF bispecific antibody ivonescimab, next-generation CD47 monoclonal antibody ligufalimab, and co...
2024-09-06 08:54
2145
Baird Medical and ExcelFin Acquisition Corp Announce Effectiveness of Registration Statement
FORT MILL, S.C., Sept. 5, 2024 /PRNewswire/ -- Betters Medical Investment
Holdings Limited ("Baird Medical" or the "Company"), a leading microwave
ablation ("MWA") medical device developer and provider inChina, and ExcelFin
Acquisition Corp. ("ExcelFin") (NASDAQ:XFIN
2024-09-06 05:23
3704
A Small Step towards a Big Mission! World's First! UltraDx Received First Clinical Approval of Single-Molecule Analyzer, in China
SHANGHAI, Sept. 5, 2024 /PRNewswire/ -- UltraDx Bio is proud to announce that its flagship product, the UD-X™ Fully Automated Single-Molecule Array Fluorescence Immunoassay Analyzer, has received its first clinical registration approval inChina. This groundbreaking achievement is now officially l...
2024-09-05 20:35
2556
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation
* Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discovery and screening technology platforms * Transactio...
2024-09-05 20:00
3202
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 320 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 319 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 278 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 257 media titles]
2026-02-17 14:16SMU MBA Rises in FT Global Rankings, Excelling in ESG, Salary and Value-for-Money
[Picked up by 251 media titles]
2026-02-16 08:00